This historical study used genetically modified mice and experimental autoimmune encephalomyelitis. Its proposed relevance to human MS is a research interpretation, not proof of a cause of MS or a treatment recommendation.
Free full text at:
http://www.jci.org/cgi/content/full/113/7/990
J Clin Invest. 2004 Apr;113(7):990-7
Waldner H, Collins M, Kuchroo VK.
Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Cambridge, Massachusetts, USA.
We describe the generation of mice that express a transgenic T cell receptor (TCR) (5B6) specific for the encephalitogenic myelin proteolipid protein (PLP) peptide 139-151, on the experimental autoimmune encephalomyelitis-resistant (EAE-resistant) B10.S background.
Despite harboring a high frequency of self-reactive T cells, 5B6 transgenic mice on the B10.S background rarely develop spontaneous EAE, which is in striking contrast to 5B6 transgenic mice on the EAE-susceptible SJL background.
The relative resistance to spontaneous EAE in transgenic B10.S mice is not due to deletion or anergy of T cells, but appears to be controlled by APCs.
Analysis of APCs revealed a lower activation state and a lower T cell-activating capacity for APCs from B10.S mice than for those from EAE-susceptible SJL mice.
When APCs in 5B6 transgenic B10.S mice were activated, for example, via TLR9 or TLR4, T cell tolerance was broken, resulting in EAE.
Our findings demonstrate that activation of APCs via innate immune receptors can break self tolerance and trigger the development of autoimmunity even in a genetically resistant strain.
These findings suggest that the development of autoimmune diseases such as multiple sclerosis is determined at least partly by the endogenous activation state of APCs.
Source details
Author: Waldner H, Collins M, Kuchroo VK.
Archive capture: . This is not a medical review date.